Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;28(1):33-37.
doi: 10.1136/ejhpharm-2019-001870. Epub 2019 May 4.

Study of clinical experience with different approaches to controlled ovarian hyperstimulation: a focus on safety and efficacy

Affiliations

Study of clinical experience with different approaches to controlled ovarian hyperstimulation: a focus on safety and efficacy

Svetoslav Stoev et al. Eur J Hosp Pharm. 2021 Jan.

Abstract

Objectives: Current retrospective cohort study analyses clinical database records of 4792 assisted reproduction procedures to assess the significance of target effectiveness endpoints from a safety perspective.

Methods: Stimulation protocols with urinary, recombinant or combination of both types gonadotrophin preparations are compared according to the following primary endpoints: incidence of ovarian hyperstimulation syndrome (OHSS), cycle cancellation, follicle count, induced estradiol values, clinical pregnancy achieved and cycles reached embryo transfer/freezing. We have investigated the incidence of cases evaluated as 'risky for OHSS' by secondary efficacy endpoints (exogenous gonadotrophin exposure, luteinising hormone and progesterone values, oocyte yield, eggs with normal maturation). The following statistical methods were applied: descriptive statistics, Mann-Whitney U test, Kruskal-Wallis test, Pearson chi-square test, Fisher's exact test, binary logistic regression.

Results: Only 16 cases (0.42%) of moderate and delayed OHSS were established. Three hundred and seven (8.6%) stimulation cycles have been cancelled, principally among urinary protocols. Although the clinical pregnancy rate does not differ significantly in compared groups, punctured follicle count, oocyte yield and progesterone level were higher for recombinant preparations, followed by combined and urinary protocols. Follicle count, mean estradiol and luteinising hormone levels are within the 'safe window' for all investigated groups, associated with minimised risk of stimulation cancellation. The mean follicle-stimulating hormone (FSH) dose was highest in urinary protocols at the same duration of stimulation compared with recombinant products. The younger age, bigger follicle count, oocytes yield, mature oocytes count, percentage of fertilised oocytes, more embryos transferred and the later day of embryo transfer are critical for both assisted reproduction techniques (ART) success rate and the safety profile of sterility treatment.

Conclusions: Safety surveillance of ART exceeds the incidence of OHSS. Suboptimal effectiveness of stimulation protocols may also jeopardise the well-being of ART patients. Gonadotrophin exposure, induced values of sex hormones, and quantity and quality of extracted oocytes should be considered to minimise any unintended suffering of treated couples.

Keywords: assisted reproduction; controlled ovarian hyperstimulation; drug effectiveness; gonadotrophin; medication safety; ovarian hyperstimulation syndrome.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum Reprod Update 2015;21:411–26. 10.1093/humupd/dmv016 - DOI - PubMed
    1. Mascarenhas MN, Flaxman SR, Boerma T, et al. . National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med 2012;9:e1001356. 10.1371/journal.pmed.1001356 - DOI - PMC - PubMed
    1. Pennings G, Ombelet W. Coming soon to your clinic: patient-friendly ART. Hum Reprod 2007;22:2075–9. 10.1093/humrep/dem158 - DOI - PubMed
    1. Sterrenburg MD, Veltman-Verhulst SM, Eijkemans MJC, et al. . Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. Hum Reprod Update 2011;17:184–96. 10.1093/humupd/dmq041 - DOI - PubMed
    1. Humaidan P, Chin W, Rogoff D, et al. . Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod 2017;32:1537–8. 10.1093/humrep/dex208 - DOI - PMC - PubMed

MeSH terms

Substances